Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Central European Media Enterprises Ltd. Reports Results for the Three Months Ended March 31, 2019

Published

on

Reading Time: 11 minutes

– Net revenues decreased 7% at actual rates but increased 2% at
constant rates to US$ 146.6 million –

– Operating income increased 12% at actual rates and 23% at constant
rates to US$ 27.6 million –

– OIBDA increased 8% at actual rates and 18% at constant rates to US$
38.1 million –

HAMILTON, Bermuda–(BUSINESS WIRE)–Central European Media Enterprises Ltd. (“CME” or the “Company”)
(NASDAQ/Prague Stock Exchange – CETV) today announced financial results
for the three months ended March 31, 2019.

Operational and financial highlights:

  • TV advertising revenues decreased 10% at actual rates and 2% at
    constant rates in the quarter. In the first four months of 2019, which
    normalizes the phasing of spending around Easter, TV ad revenues are
    estimated to have increased 3% at constant rates compared to the same
    period in 2018.
  • Carriage fees and subscription revenues increased 4% at actual rates
    and 12% at constant rates in the first quarter.
  • Costs charged in arriving at OIBDA decreased 11% at actual rates and
    3% at constant rates.
  • OIBDA margin increased by 360 basis points to 26%.
  • Cash generated from continuing operating activities increased 34% at
    actual rates to US$ 96.0 million.
  • Unlevered free cash flow increased 33% at actual rates to US$ 94.7
    million.
  • CME repaid EUR 60 million of debt from cash generated by the business,
    which together with the improvement in our operations reduced our net
    leverage ratio to 3.0x at the end of March from 3.5x at the start of
    the year.

Michael Del Nin, Co-Chief Executive Officer, commented: “The year has
gotten off to an outstanding start, exceeding our previous expectations
to such an extent that we are raising our guidance for 2019. With the
highest Q1 margin in more than a decade, an 18% improvement in
like-for-like OIBDA, and a more than 30% surge in unlevered free cash
flow, these are among the best Q1 results in the history of the company.
Furthermore, they are bolstered by around 20% growth in TV ad revenues
in our two largest markets in April, pushing year-to-date sales well
into positive territory after the first quarter was impacted by both
sector taxes in Romania and the phasing of spending related to the
timing of Easter this year.”

Christoph Mainusch, Co-Chief Executive Officer, added: “With the
successful launch of the spring season during the first quarter, our
main channel in four countries increased year-to-date audience share in
both prime time and all day. Carriage fees have transformed the
predictability and profitability of several of our businesses, with four
segments now seeing margins of more than 25% in Q1. Facing various
headwinds in the quarter, we grew our TV ad revenues in three segments,
and we increased market share in four of five countries.”

In this release we refer to several non-GAAP financial measures,
including OIBDA, OIBDA margin, free cash flow, unlevered free cash flow
and constant currency percentage movements. Please see “Non-GAAP
Financial Measures” below for additional information, including
definitions and reconciliations to US GAAP financial measures.

Consolidated results for the three months ended March 31, 2019 and 2018
were:

(US$ 000’s, except per share data)     For the Three Months Ended March 31,

(unaudited)

 

2019

       

2018

     

% Actual

   

% Lfl (1)

Net revenues $ 146,559 $ 156,709 (6.5)% 1.6%
Operating income 27,637 24,581 12.4% 23.2%
Operating margin 18.9 % 15.7 % 3.2 p.p. 3.3 p.p.
OIBDA 38,057 35,324 7.7% 17.7%
OIBDA margin 26.0 % 22.5 % 3.5 p.p. 3.6 p.p.
Income from continuing operations 11,751 6,756 73.9% 96.6%
Income from continuing operations per share – basic 0.03 0.02 86.9% 127.0%
Income from continuing operations per share – diluted $ 0.03 $ 0.01 144.8% 197.3%
(1) % Lfl (like-for-like) variance reflects the impact of
applying the current period average exchange rates to the prior
period revenues and costs.
 

Teleconference and Audio Webcast Details

CME will host a teleconference and audio webcast to discuss its first
quarter results on Tuesday, April 30, 2019 at 9 a.m. New York time (2
p.m. London and 3 p.m. Prague time). The audio webcast and
teleconference will refer to presentation slides which will be available
on CME’s website at www.cme.net
prior to the call.

To access the teleconference, U.S. and international callers may dial
+1-647-689-5402 ten minutes prior to the start time and reference
conference ID 2273725. The conference call will also be audio webcasted
via www.cme.net.
It can be heard on iPads, iPhones and a range of devices supporting
Android and Windows operating systems.

A digital audio replay of the webcast will be available for two weeks
following the call at www.cme.net.

Forward-Looking and Cautionary Statements

This press release contains forward-looking statements. For all
forward-looking statements, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are inherently
subject to risks and uncertainties, many of which cannot be predicted
with accuracy or are otherwise beyond our control and some of which
might not even be anticipated.
Forward-looking statements reflect
our current views with respect to future events and because our business
is subject to such risks and uncertainties, actual results, our
strategic plan, our financial position, results of operations and cash
flows could differ materially from those described in or contemplated by
the forward-looking statements.

Important factors that contribute to such risks include, but are not
limited to, those factors set forth under “Risk Factors” in our
Quarterly Report on Form 10-Q for the period ended March 31, 2019 as
well as the following: the effect of changes in global and regional
economic conditions; the impact of ending the quantitative easing
program implemented by the European Central Bank; the economic,
political and monetary impacts of Brexit in our markets; the outcome of
our strategic review and its impact on our business; the impact of
changes in local tax legislation and the timing of public holidays on
advertising spending; levels of television advertising spending and the
rate of development of the advertising markets in the countries in which
we operate; our ability to refinance our existing indebtedness; the
extent to which our debt service obligations and covenants may restrict
our business; our exposure to additional tax liabilities as well as
liabilities resulting from regulatory or legal proceedings initiated
against us; our success in continuing our initiatives to diversify and
enhance our revenue streams; our ability to make cost-effective
investments in our television businesses, including investments in
programming; our ability to develop and acquire necessary programming
and attract audiences; and changes in the political and regulatory
environments where we operate and in the application of relevant laws
and regulations.

The foregoing review of important factors should not be construed as
exhaustive. For a more detailed description of these uncertainties and
other factors, please see the “Risk Factors” and “Forward-looking
Statements” sections in CME’s Quarterly Report on Form 10-Q for the
period ended March 31, 2019. We undertake no obligation to publicly
update or review any forward-looking statements, whether as a result of
new information, future developments or otherwise.

This press release should be read in conjunction with our Quarterly
Report on Form 10-Q for the period ended March 31, 2019, which was filed
with the Securities and Exchange Commission on April 30, 2019.

We make available free of charge on our website at www.cme.net
our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and amendments to those reports as soon as
reasonably practicable after we electronically file such material with,
or furnish it to, the Securities and Exchange Commission. Please note
that we may announce material information using SEC filings, press
releases, public conference calls, webcasts and posts to the Investors
section of our website, www.cme.net.
In the future, we will continue to use these channels to communicate
important information about CME and our operations. Information that we
post on our website could be deemed material. Therefore, we encourage
investors, the media, our customers and others interested in CME to
review the information we post at www.cme.net.

CME is a media and entertainment company operating leading businesses in
five Central and Eastern European markets with an aggregate population
of approximately 45 million people. CME’s operations broadcast 30
television channels in Bulgaria (bTV, bTV Cinema, bTV Comedy, bTV
Action, bTV Lady and Ring), the Czech Republic (Nova, Nova 2, Nova
Cinema, Nova Sport 1, Nova Sport 2, Nova International, Nova Action and
Nova Gold), Romania (PRO TV, PRO 2, PRO X, PRO GOLD, PRO CINEMA, PRO TV
International and PRO TV Chisinau), the Slovak Republic (TV Markíza,
Markíza International, Doma and Dajto) and Slovenia (POP TV, Kanal A,
Brio, Oto and Kino). CME is traded on the NASDAQ Global Select Market
and the Prague Stock Exchange under the ticker symbol “CETV”.

 

CENTRAL EUROPEAN MEDIA ENTERPRISES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(US$ 000’s, except share and per share data)

(unaudited)

 
For the Three Months Ended March 31,
 

2019

     

2018

 
Net revenues $ 146,559 $ 156,709
Operating expenses:
Content costs 70,360 78,460
Other operating costs 13,248 14,467
Depreciation of property, plant and equipment 8,226 8,387
Amortization of broadcast licenses and other intangibles 2,194   2,356  
Cost of revenues 94,028 103,670
Selling, general and administrative expenses 24,894   28,458  
Operating income 27,637 24,581
Interest expense (8,242 ) (17,818 )
Other non-operating (expense) / income, net (3,097 ) 4,208  
Income before tax 16,298 10,971
Provision for income taxes (4,547 ) (4,215 )
Income from continuing operations 11,751 6,756
Income from discontinued operations, net of tax   316  
Net income 11,751 7,072
Net loss attributable to noncontrolling interests 7   178  
Net income attributable to CME Ltd. $ 11,758   $ 7,250  
 
PER SHARE DATA:
Net income per share:
Continuing operations — basic $ 0.03 $ 0.02
Continuing operations — diluted 0.03 0.01
Discontinued operations — basic 0.00
Discontinued operations — diluted 0.00
Attributable to CME Ltd. — basic 0.03 0.02
Attributable to CME Ltd. — diluted $ 0.03 $ 0.01
 
Weighted average common shares used in computing per share
amounts (000’s):
Basic 264,199 158,039
Diluted 265,211 241,905
 
 

CENTRAL EUROPEAN MEDIA ENTERPRISES LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

(US$ 000’s)

(unaudited)

   
March 31, 2019 December 31, 2018
ASSETS
Cash and cash equivalents $ 80,032 $ 62,031
Other current assets 263,098   312,062  
Total current assets 343,130 374,093
Property, plant and equipment, net 110,347 117,604
Goodwill and other intangible assets, net 968,225 984,256
Other non-current assets 23,967   12,408  
Total assets $ 1,445,669   $ 1,488,361  
 
LIABILITIES AND EQUITY
Accounts payable and accrued liabilities $ 127,222 $ 120,468
Current portion of long-term debt and other financing arrangements 5,802 5,545
Other current liabilities 38,453   13,679  
Total current liabilities 171,477 139,692
Long-term debt and other financing arrangements 700,694 782,685
Other non-current liabilities 81,526   67,293  
Total liabilities $ 953,697   $ 989,670  
 
Series B Convertible Redeemable Preferred Stock $ 269,370 $ 269,370
 
EQUITY
Common Stock $ 20,262 $ 20,228
Additional paid-in capital 2,004,188 2,003,518
Accumulated deficit (1,566,318 ) (1,578,076 )
Accumulated other comprehensive loss (235,961 ) (216,650 )
Total CME Ltd. shareholders’ equity 222,171 229,020
Noncontrolling interests 431   301  
Total equity 222,602   229,321  
Total liabilities and equity $ 1,445,669   $ 1,488,361  
 
 

CENTRAL EUROPEAN MEDIA ENTERPRISES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(US$ 000’s)

(unaudited)

     
For the Three Months
Ended March 31,
 

2019

     

2018

 
Net cash generated from continuing operating activities $ 96,009 $ 71,495
Net cash used in continuing investing activities (4,359 ) (5,353 )
Net cash used in continuing financing activities (71,736 ) (60,526 )
Net cash provided by discontinued operations 9,554
Impact of exchange rate fluctuations on cash and cash equivalents (1,913 ) 2,515  
Net increase in cash and cash equivalents $ 18,001   $ 17,685  
 
Supplemental disclosure of cash flow information:
Cash paid for interest (including guarantee fees) $ 3,093 $ 4,883
Cash paid for income taxes, net of refunds $ 6,318 $ 4,120
 
Supplemental disclosure of non-cash financing activities:
Accretion on Series B Convertible Redeemable Preferred Stock $ $ 2,447
 

Segment Data

We manage our business on a geographical basis, with five reporting
segments: Bulgaria, the Czech Republic, Romania, the Slovak Republic and
Slovenia. These segments reflect how CME Ltd.’s operating performance is
evaluated by our chief operating decision makers, who we have identified
as our co-Chief Executive Officers, how operations are managed by
segment managers, and the structure of our internal financial reporting.

We evaluate our consolidated results and the performance of our segments
based on net revenues and OIBDA. Intersegment revenues and profits have
been eliminated in consolidation.

Below are tables showing our net revenues and OIBDA by segment for the
three months ended March 31, 2019 and 2018:

(US$ 000’s)       For the Three Months Ended March 31,

(unaudited)

 

2019

     

2018

   

% Actual

 

% Lfl (1)

Net revenues

Bulgaria $ 19,293 $ 19,433 (0.7 )% 6.9 %
Czech Republic 50,316 51,534 (2.4 )% 6.4 %
Romania 38,810 45,961 (15.6 )% (7.5 )%
Slovak Republic 21,332 22,953 (7.1 )% 0.1 %
Slovenia 17,850 17,530 1.8 % 9.6 %
Intersegment revenues (1,042 ) (702 ) NM (2) NM (2)
Total net revenues $ 146,559   $ 156,709   (6.5 )% 1.6 %
 
(US$ 000’s) For the Three Months Ended March 31,

(unaudited)

 

2019

   

2018

 

% Act

% Lfl (1)

OIBDA

Bulgaria $ 6,121 $ 2,981 105.3 % 121.2 %
Czech Republic 14,947 15,370 (2.8 )% 6.1 %
Romania 17,533 18,893 (7.2 )% 1.7 %
Slovak Republic 1,729 1,103 56.8 % 71.5 %
Slovenia 4,931 4,653 6.0 % 14.1 %
Elimination 48   16   NM (2) NM (2)
Total Operating Segments 45,309 43,016 5.3 % 14.9 %
Corporate (7,252 ) (7,692 ) 5.7 % (2.2 )%
Total OIBDA $ 38,057   $ 35,324   7.7 % 17.7 %
 
(1) % Lfl (like-for-like) variance reflects the impact of
applying the current period average exchange rates to the prior
period revenues and costs.

(2) Number is not meaningful.

 

Non-GAAP Financial Measures

In this release we refer to several non-GAAP financial measures,
including OIBDA, OIBDA margin, free cash flow and unlevered free cash
flow. We believe that each of these metrics is useful to investors for
the reasons outlined below. Non-GAAP financial measures may not be
comparable to similar measures reported by other companies. Non-GAAP
financial measures should be evaluated in conjunction with, and are not
a substitute for, US GAAP financial measures.

We evaluate our consolidated results and the performance of our segments
based on net revenues and OIBDA. We believe OIBDA is useful to investors
because it provides a meaningful representation of our performance, as
it excludes certain items that do not impact either our cash flows or
the operating results of our operations. OIBDA and unlevered free cash
flow are also used as components in determining management bonuses.

OIBDA includes amortization and impairment of program rights and is
calculated as operating income / loss before depreciation, amortization
of intangible assets and impairments of assets and certain unusual or
infrequent items that are not considered by our co-Chief Executive
Officers when evaluating our performance. Our key performance measure of
the efficiency of our consolidated operations and our segments is OIBDA
margin. We define OIBDA margin as the ratio of OIBDA to net revenues.

Following a repricing of our Guarantee Fees in March 2017 and April
2018, we pay interest and related Guarantee Fees on our outstanding
indebtedness in cash. In addition to this obligation to pay Guarantee
Fees in cash, we expect to use cash generated by the business to pay
certain Guarantee Fees that were previously paid in kind. These cash
payments are all reflected in free cash flow; accordingly we believe
unlevered free cash flow, defined as free cash flow before cash payments
for interest and Guarantee Fees, best illustrates the cash generated by
our operations when comparing periods. We define free cash flow as net
cash generated from continuing operating activities less purchases of
property, plant and equipment, net of disposals of property, plant and
equipment and excluding the cash impact of certain unusual or infrequent
items that are not included in costs charged in arriving at OIBDA
because they are not considered by our co-Chief Executive Officers when
evaluating performance. For additional information regarding our
business segments, see Item 1, Note 19, “Segment Data” in our Form 10-Q.

While our reporting currency is the dollar, our consolidated revenues
and costs are divided across a range of European currencies and CME
Ltd.’s function currency is the Euro. Given the significant movement of
the currencies in the markets in which we operate against the dollar, we
believe that it is useful to provide percentage movements based on
actual percentage movements (“% Act”), which includes the effect of
foreign exchange, as well as like-for-like percentage movements (“%
Lfl”). The like-for-like percentage movement references reflect the
impact of applying the current period average exchange rates to the
prior period revenues and costs. Since the difference between
like-for-like and actual percentage movements is solely the impact of
movements in foreign exchange rates, our discussion in this release
includes constant currency percentage movements in order to highlight
those factors influencing operational performance. The incremental
impact of foreign exchange rates is presented in the tables accompanying
such analysis.

   
(US$ 000’s) For the Three Months Ended March 31,
(unaudited) 2019     2018  
Operating income $ 27,637 $ 24,581
Depreciation of property, plant and equipment 8,226 8,387
Amortization of intangible assets 2,194   2,356  
Total OIBDA $ 38,057   $ 35,324  
 
(US$ 000’s) For the Three Months Ended March 31,
(unaudited) 2019   2018  
Net cash generated from continuing operating activities $ 96,009 $ 71,495
Capital expenditures, net of proceeds from disposals (4,359 ) (5,353 )
Free cash flow 91,650 66,142
Cash paid for interest (including mandatory cash-pay guarantee fees) 3,093   4,883  
Unlevered free cash flow from continuing operating activities $ 94,743   $ 71,025  

Contacts

For additional information, please visit www.cme.net
or contact:
Mark Kobal
Head of Investor Relations
Central
European Media Enterprises
+420 242 465 576
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives

Published

on

Continue Reading

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania